The structure of cell surface glycan groups plays a key regulatory role in normal physiological states and the development of diseases. Many diseases, such as cancer, cardiovascular diseases, and immune-related diseases, are closely related to abnormal changes in cell surface glycan groups. Cell surface glycoengineering helps researchers study the mechanisms of disease onset. Many diseases often lack obvious symptoms in their early stages, and traditional detection methods have limitations. In contrast, abnormal changes in cell surface glycan groups are often associated with early disease development. By introducing specific sugar group markers to the cell surface, more accurate and sensitive disease detection methods can be provided to facilitate early disease detection and prevention. By modulating the structure of glycan groups on the surface of tumor cells, the ability of the immune system to recognize and attack tumors can be enhanced, and new immunotherapeutic approaches can be developed.
Fig.1 Overview of the applications of metabolic glycoengineering in cells. (Ying, et al., 2022)
CD BioGlyco has established a comprehensive Glycoengineering Platform to offer a variety of technologies for cell surface glycoengineering such as metabolic pathways, chemical conjugation, liposome fusion, and genetic methods. The specifics of the services we provide are outlined below:
CD BioGlyco specializes in providing technologies for cell surface glycoengineering. Our services meet the needs of our clients in the areas of biomedical research, drug discovery, and disease research. Besides, our technologies can be applied to different types of cells and biological systems with a wide range of applicability. If you need the related services mentioned above, please contact us for more information.
Reference